Polymorphisms (Alleles 1/2) | Groups | n | Genotypes | Genotypic comparison | χ 2 (2 × 2) (df = 2) | p | Cramer’s V | ||
---|---|---|---|---|---|---|---|---|---|
1/1 | 1/2 | 2/2 | |||||||
ACTN3 (R/X) | Controls | 450 | 162 (36.0%) | 205 (45.6%) | 83 (18.4%) | Control vs. Elite | 3.97 | 0.137 | 0.092 |
All athletes | 123 | 35 (28.5%) | 56 (45.5%) | 32 (26.0%) | Control vs. All athletes | 4.36 | 0.113 | 0.087 | |
Sub-elite | 104 | 32 (30.8%) | 46 (44.2%) | 26 (25.0%) | Control vs. Sub-elite | 2.54 | 0.218 | 0.068 | |
Elite | 19 | 3 (15.8%) | 10 (52.6%) | 6 (31.6%) | Elite vs. Sub-elite | 1.78 | 0.410 | 0.120 | |
Sub-elite Pow | 85 | 25 (29.4%) | 38 (44.7%) | 22 (25.9%) | Sub-elite Pow vs. Elite Pow | 1.52 | 0.468 | 0.120 | |
Sub-elite End | 19 | 7 (36.8%) | 8 (42.1%) | 4 (21.1%) | Sub-elite End vs. Sub-elite Pow | 1.03 | 0.596 | 0.100 | |
Elite Pow | 13 | 2 (15.4%) | 8 (61.5%) | 3 (23.1%) | Elite Pow vs. Elite End | 1.57 | 0.457 | 0.290 | |
Elite End | 6 | 1 (16.7%) | 2 (33.3%) | 3 (50.0%) | Elite End vs. Sub-elite End | 2.03 | 0.362 | 0.280 | |
ACE (I/D) | Controls | 718 | 138 (19.2%) | 341 (47.5%) | 239 (33.3%) | Control vs. Elite | 3.16 | 0.206 | 0.065 |
All athletes | 123 | 19 (15.4%) | 62 (50.4%) | 42 (34.1%) | Control vs. All athletes | 1.01 | 0.604 | 0.035 | |
Sub-elite | 104 | 16 (15.4%) | 56 (53.8%) | 32 (30.8%) | Control vs. Sub-elite | 1.65 | 0.439 | 0.045 | |
Elite | 19 | 3 (15.8%) | 6 (31.6%) | 10 (52.6%) | Elite vs. Sub-elite | 3.83 | 0.147 | 0.180 | |
Sub-elite Pow | 85 | 13 (15.3%) | 46 (54.1%) | 26 (30.6%) | Sub-elite Pow vs. Elite Pow | 8.17 | 0.017* | 0.290 | |
Sub-elite End | 20 | 3 (15%) | 11 (55%) | 6 (30%) | Sub-elite End vs. Sub-elite Pow | 0.01 | 0.993 | 0.010 | |
Elite Pow | 13 | 2 (15.4%) | 2 (15.4%) | 9 (69.2%) | Elite Pow vs. Elite End | 5.58 | 0.061 | 0.540 | |
Elite End | 6 | 1 (16.7%) | 4 (66.7%) | 1 (16.7%) | Elite End vs. Sub-elite End | 0.53 | 0.769 | 0.140 | |
BDKRB2 (-9/+9) | Controls | 567 | 129 (22.8%) | 346 (50.1%) | 154 (27.1%) | Control vs. Elite | 0.47 | 0.791 | 0.028 |
All athletes | 123 | 27 (22.0%) | 62 (50.4%) | 34 (27.6%) | Control vs. All athletes | 2.07 | 0.355 | 0.055 | |
Sub-elite | 104 | 21 (20.2%) | 54 (51.9%) | 29 (27.9%) | Control vs. Sub-elite | 2.68 | 0.262 | 0.063 | |
Elite | 19 | 6 (31.6%) | 8 (42.1%) | 5 (26.3%) | Elite vs. Sub-elite | 1.27 | 0.530 | 0.100 | |
Sub-elite Pow | 85 | 19 (22.4%) | 43 (50.6%) | 23 (27.1%) | Sub-elite Pow vs. Elite Pow | 1.84 | 0.398 | 0.140 | |
Sub-elite End | 20 | 2 (10.0%) | 11 (60.0%) | 6 (30.0%) | Sub-elite End vs. Sub-elite Pow | 1.62 | 0.444 | 0.120 | |
Elite Pow | 13 | 5 (38.5%) | 6 (46.2%) | 2 (15.4%) | Elite Pow vs. Elite End | 2.65 | 0.266 | 0.370 | |
Elite End | 6 | 1 (16.7%) | 2 (33.3%) | 3 (50.0%) | Elite End vs. Sub-elite End | 1.10 | 0.576 | 0.210 | |
AGT (M/T) | Controls | 231 | 72 (31.2%) | 112 (48.5%) | 47 (20.3%) | Control vs. Elite | 3.47 | 0.177 | 0.120 |
All athletes | 114 | 41 (36.0%) | 47 (41.2%) | 26 (22.8%) | Control vs. All athletes | 1.63 | 0.443 | 0.069 | |
Sub-elite | 97 | 32 (33.0%) | 41 (42.3%) | 24 (24.7%) | Control vs. Sub-elite | 1.25 | 0.536 | 0.062 | |
Elite | 17 | 9 (52.9%) | 6 (35.3%) | 2 (11.8%) | Elite vs. Sub-Elite | 2.84 | 0.242 | 0.160 | |
Sub-elite Pow | 79 | 27 (34.2%) | 32 (40.5%) | 20 (25.3%) | Sub-elite Pow vs. Elite Pow | 1.73 | 0.421 | 0.140 | |
Sub-elite End | 19 | 6 (31.6%) | 9 (47.4%) | 4 (21.1%) | Sub-elite End vs. Sub-elite Pow | 0.29 | 0.865 | 0.054 | |
Elite Pow | 11 | 6 (54.5%) | 3 (27.3%) | 2 (18.2%) | Elite Pow vs. Elite End | 1.67 | 0.433 | 0.310 | |
Elite End | 6 | 3 (50.0%) | 3 (50.0%) | 0 (0.0%) | Elite End vs. Sub-elite End | 2.00 | 0.368 | 0.260 |